Collaboration
The 3 Pillars
3 Challenging Cells to Innovate Cell and Gene Therapy
To broaden the target diseases, we aim to broaden the target cells.
Femtobiomed will ‘Scale-Out’ the transfection technology, to deliver new medicine to patients quicker.
NK
Rare population
High expansion costs
Low viral transduction efficiency Compromised viability in transduction
MSC
Safety risks of viral transduction
Low LNP transfection efficiency
Poor engraftment
iPSC
Rare population
High expansion cost
Low reprogramming efficiency
Poor engraftment
Opportunities in Cell and Gene Therapy
Overcome industry challenges in the conventional viral CAGT sector with our proposed solutions
Challenge
Femtobiomed’s
Solutions
High Price
CAR-T Therapy : 375,000 – 475,000 USD
Long Manufacturing
Process
Manufacturing 3 weeks, Shipping
> 1 week
Manufacturing
Failure Rate
22% - Out of specification issues
(Cell viability < 80%)
14% - Manufacturing failure
(Inability to meet targeted dose)
Serious Side Effets
79% - Cytokine Release Syndrome
72% - Neuronal Toxicity
Unable to cure
Solid Cancer
Absence of multiple target cell therapeutics
Difficulties of CAR-NK production
Reduced Price
CellShot enables nonviral delivery, reducing expensive raw materials
and manufacturing process costs
< 1 Day Production
Manufactured within 10 mins per dose, within 1 Day including QC
High Cell Viability
& Production Yield
CellShot RTX reduces manufacturing failure rates and maximizes patient treatment potential by shortening production time
mRNA Transfection
Eliminating side effects through mRNA delivery and opening the possibilities of the multi-dosing cell therapeutics
Multi-target
CAR-NK
Solid cancer treatment through mRNA-based multi-target CAR-NK with improved efficacy and production yield
Proof of Concept
PoC Domains
Targeting cells and materials that go beyond the limits of existing technologies.
Flow cytometric analysis of enhanced Green Fluorescent Protein (eGFP) mRNA was used to determine the viability and transfection efficiency after electroporation. The transfected PBMCs resulted a viability of 98.1% and an efficiency of 91.5%.
CAR-CD19 mRNA was transfected to Human Primary NK cells using CellShot® Partitioned Flow Transfection, which resulted in 97.1% CAR expression and 96.7% cell viability after electroporation.
CAR-CD19 mRNA was transfected to Human NK cell lines using CellShot® Partitioned Flow Transfection system, which resulted in 84.9% CAR expression and 94.0% cell viability after electroporation.
CAR-NK cells demonstrated highly potent and specific killing capabilities in vitro. CAR-NK exerted much higher cytotoxicity against the Nalm6 cells (P < 0.01 by two-tailed t-test for all comparisons at each Effector cell : Target cell ratio; E:T ratio.) than the non-transfected hNK cells (NT NK). To determine whether CAR-CD19-expressed hNK cells have cytotoxicity against Normal B cells expressing CD19, we performed tests using the GA-10 cell line as a target cell.
Flow cytometric analysis of enhanced Green Fluorescent Protein (eGFP) mRNA was used to determine viability and transfection efficiency after EP. The transfected NK cells resulted a viability of 94.3% and an efficiency of 99.4%.
Flow cytometric analysis of enhanced Green Fluorescent Protein (eGFP) mRNA was used to determine viability and transfection efficiency after EP. The transfected T cells resulted a viability of 95.6% and an efficiency of 94.8%.
Flow cytometric analysis of enhanced Green Fluorescent Protein (eGFP) mRNA was used to determine viability and transfection efficiency after EP. The transfected HepG2 cells resulted a viability of 99.0% and an efficiency of 92.2%.
CellShot Partitioned Flow Transfection system achieves 76% cell viability and transfection efficiency in HepG2 cells delivering plasmid DNA sized of 6.6 kb.
Enablement of Sequential cell engineering through Partitioned Flow Transfection at 20% reduced viability and higher efficiency at 4th transfection against single transfection (positive control).